Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a developer of prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology and its lead product candidate, an abuse-deterrent fentanyl patch. The Nutriband news stream highlights how the company is advancing this technology platform, interacting with regulators, and managing its corporate structure to support product development.
Readers of the Nutriband news page can follow regulatory and clinical development updates, including the company’s reported meetings with the U.S. Food and Drug Administration on the Chemistry, Manufacturing, and Controls plans and the 505(b)(2) NDA pathway for AVERSA Fentanyl. News items also cover Nutriband’s summaries of FDA feedback on in vitro studies to characterize abuse-deterrent properties and its intention to move toward an IND filing in support of a Human Abuse Potential clinical study.
The company’s releases also describe intellectual property developments, such as a provisional patent application to enhance AVERSA technology and U.S. patent actions related to abuse and misuse deterrent transdermal systems, alongside references to a broad patent portfolio covering AVERSA in multiple countries. Corporate and capital markets news includes announcements of a preferred stock dividend tied to future FDA approval of AVERSA Fentanyl, the sale of a majority stake in subsidiary Pocono Pharmaceutical to EarthVision Bio, and Nutriband’s inclusion in Russell indexes.
Additional coverage includes partnership and collaboration news, such as agreements with Kindeva Drug Delivery for product development, Brand Institute for commercial brand name creation, and a non-binding Letter of Intent with the Qvanta Group to explore advanced technology support for abuse-deterrent pharmaceutical innovation. Investors and observers can use this page to review how Nutriband presents its progress on AVERSA Fentanyl, its stance on issues like illicit versus prescription fentanyl, and its participation in investor conferences and public communications.
Nutriband Inc. (NASDAQ:NTRB) has achieved a significant milestone with its inclusion in four Russell indexes: the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, and Russell 3000E Growth Index as part of the 2025 Russell indexes reconstitution.
CEO Gareth Sheridan highlighted the company's AVERSA pipeline development, particularly AVERSA Fentanyl, which has a projected peak annual US sales potential of $80 million to $200 million. The company aims to enhance the safety profile of easily abused medications while ensuring availability to patients in need.
The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. FTSE Russell will transition to a semi-annual reconstitution frequency starting in 2026.
Nutriband CEO Gareth Sheridan released a shareholder letter highlighting the company's achievements in 2024 and outlook for 2025. The company is developing AVERSA technology, aimed at creating the world's first abuse-deterrent transdermal drug delivery system.
In partnership with Kindeva Drug Delivery, Nutriband is developing AVERSA Fentanyl, projected to reach peak annual sales of $80M-$200M. Their second product, AVERSA Buprenorphine, is estimated to achieve $70M-$130M in peak annual sales. The company secured $8.4M through private placement in April 2024 and expanded its patent portfolio to 46 countries.
Key 2025 objectives include:
- Conducting Human Abuse Liability clinical trials for AVERSA Fentanyl
- Filing an Investigational New Drug application with FDA
- Exploring international partnerships
- Growing revenue through Pocono Pharma subsidiary's kinesiology tape manufacturing
Nutriband Inc. (NASDAQ:NTRB) has secured a patent in Macao for its AVERSA abuse deterrent transdermal technology. The patent, J/9010, was granted on February 11, 2025, protecting the company's 'Abuse and Misuse Deterrent Transdermal Systems.'
AVERSA technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs with high abuse potential, such as opioids and stimulants.
The company is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the first abuse-deterrent opioid patch globally. The product aims to deter abuse and reduce accidental exposure risks, with projected peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) has announced signing an Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which they position as potentially becoming the world's first abuse deterrent patch platform for chronic pain management.
Nutriband Inc. (NASDAQ:NTRB) has announced a new Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which is being developed as a potential first-of-its-kind abuse deterrent patch platform for chronic pain management.
Nutriband (NASDAQ: NTRB) has secured a Certificate of Registration from the USPTO for trademark registration Number 7,692,920 on February 18, 2025. The trademark covers product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development under Class 042.
The Nutriband™ trademark is important for commercializing the company's AVERSA platform technology, designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's leading product, AVERSA™ Fentanyl, is being developed in partnership with Kindeva Drug Delivery, focusing on scaling up commercial manufacturing before FDA submission. Market analysis by Health Advances projects potential peak annual U.S. sales of $80-200 million for AVERSA™ Fentanyl.